Swiss Severe Asthma Register (SAR)

Asthma is a chronic respiratory airway disease that affects more than 300 million people worldwide. Severe Asthma (SA) affects around 5-10% of all asthma patients yet accounts for half of the asthma related costs and carries a high burden of disease . Since the introduction of highly targeted treatments (monoclonal antibodies) in 2005, the treatment of severe asthma has been revolutionized. Nowadays, most of the patients with a severe asthma are treated with monoclonal antibodies. However, in Switzerland as in other countries, we have had only a little knowledge about the real-life situation of patients with SA, regarding long-term clinical management and therapeutic outcomes. Recognizing that knowledge gap, multiple countries, including Switzerland, have established national registries observing severe asthma and build up an international network of clinical registries.

The overall aim of this cohort is to gain comprehensive information about severe asthma in Switzerland, with the focus on the following:

• Describing SA Patient characteristics in Switzerland
• Treatment regimens over time
• Clinical course of SA patients over time including changes and influencing factors of asthma related outcomes